Curis, Inc.

CRIS

NASDAQ

Healthcare

Biotechnology

Lexington, MA, US34 employeescuris.com

$0.55

+0.02(3.19%)

Mkt Cap $7M

$0.51

$2.80

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Gross Royalty Revenue (100%).

8-K

Curis, Inc. announced financial results for the three- and twelve-month periods ended December 31, 2025, reporting Q4 net income of $19.4 million ($1.23 per share) versus a $9.6 million net loss in Q4 2024, and full-year net loss of $7.6 million ($0.58 per share) versus $43.4 million in 2024. Updates included clinical data from lymphoma and leukemia trials and a January 2026 PIPE financing with up to $80.8 million in gross proceeds.

$7M

Market Cap

$985.3K

Revenue

-$791.1K

Net Income

Employees34

Fundamentals

How The Business Makes Money

Revenue by Segment

Gross Royalty Revenue100%($21M)

Activity

What Changed Recently

Delisting

Feb 8, 2026

. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 3, 2026, Curis, Inc. (the “Company”) received

Financial Results

Mar 18, 2026

. Results of Operations and Financial Condition. On March 19, 2026, Curis, Inc. announced its financial results for the three- and twelve-month periods ended De

Material Agreement+4 More

Jan 7, 2026

Entry into a Material Definitive Agreement. Securities Purchase Agreement On January 7, 2026, Curis, Inc. (the “Company”) entered into a Securities Purchase Agr

Peer Companies

Company	Price	Change	Market Cap	P/E
PALIPalisade Bio, Inc.	$1.90	+0.80%	$314M	-6.3
LPTXLeap Therapeutics, Inc.	$0.77	-3.15%	$32M	-2.6
ATHAATHA	$6.75	-6.12%	$27M	—
ENTOENTO	$2.85	-5.00%	$14M	—
ICUSeaStar Medical Holding C...	$4.46	+25.42%	$12M	-0.4
CTXRCitius Pharmaceuticals, I...	$0.85	+1.30%	$10M	-0.5
BCTXBriaCell Therapeutics Cor...	$4.08	-1.57%	$8M	-0.3
HOTHHoth Therapeutics, Inc.	$0.57	+3.25%	$7M	-1.1

Analyst View

Company Profile

CIK0001108205

ISINUS2312693094

CUSIP231269200

Phone617 503 6500

AddressBuilding C, Lexington, MA, 02421, US

SEC EDGAR